Arthritis & Rheumatology is a leading journal dedicated to the advancement of knowledge in the fields of rheumatology, immunology, and allergy. Published by WILEY in the United Kingdom, this prestigious journal boasts an impressive impact factor and a prominent reputation, ranking in the Q1 category across multiple disciplines, including Immunology and Rheumatology. With its high ranking of 4th out of 73 in Rheumatology and notable standings in related fields, it serves as a crucial platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings. The journal embraces an Open Access model, enhancing the accessibility of vital research to a global audience and ensuring that knowledge dissemination is maximized. Since its inception in 2014, Arthritis & Rheumatology has been at the forefront of impactful research, fostering collaboration and innovation in tackling complex challenges within these medical disciplines. Researchers looking to explore the latest advancements and engage with cutting-edge studies in these fields will find this journal to be an essential resource.

Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Current Opinion in Rheumatology, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of rheumatology. Since its inception in 1989, this prestigious journal has been at the forefront of disseminating cutting-edge research, with a notable Q1 ranking in the 2023 Rheumatology category and an impressive Scopus rank of 7 out of 73, placing it in the 91st percentile. The journal's commitment to presenting insightful reviews and critical analyses of recent advancements and treatment strategies makes it an essential read for professionals, researchers, and students dedicated to the study of rheumatic diseases. Although not an open-access journal, Current Opinion in Rheumatology continues to foster an informed dialogue within the academic community through its high-impact content, ensuring that the latest developments and practices are accessible to those at the vanguard of rheumatology research.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.

Rheumatology Advances in Practice, published by Oxford University Press, is a vital open-access journal dedicated to advancing research and education in the field of rheumatology. With an E-ISSN of 2514-1775 and an impressive open access model established since 2017, this journal facilitates the dissemination of cutting-edge knowledge and innovative practices to a global audience. It has garnered recognition within the academic community, holding a Q3 classification in Rheumatology for 2023, which reflects its contribution to the evolving landscape of rheumatological research. The journal aims to present high-quality, peer-reviewed articles that explore the latest findings, advancements, and clinical applications in rheumatology, making it an essential resource for researchers, healthcare professionals, and students alike. By bridging the gap between research and practice, Rheumatology Advances in Practice plays a significant role in improving the care of patients with rheumatological conditions, promoting evidence-based approaches to clinical challenges.

Current Treatment Options in Rheumatology, published by SPRINGERNATURE, is a pivotal journal focused on advancing the field of rheumatology through the dissemination of cutting-edge research and comprehensive reviews. With an emphasis on current therapeutic strategies, this journal aims to provide healthcare professionals, researchers, and students with up-to-date information on the latest treatment modalities for rheumatic diseases. Although it operates under a subscription model, it offers a platform for sharing significant findings that can influence clinical practice and policy within the field of rheumatology. By promoting insightful discussions and collaborations, Current Treatment Options in Rheumatology plays a crucial role in shaping the future of rheumatic disease management and improving patient outcomes.

The International Journal of Rheumatic Diseases, published by WILEY, serves as a crucial platform for disseminating high-quality research and advancements in the field of rheumatology. With an ISSN of 1756-1841 and an E-ISSN of 1756-185X, this journal has established itself within the academic community since its inception in 2008, and it is set to continue until at least 2024. Positioned in the Q3 category of rheumatology, the journal holds a significant rank of #38 out of 73 in its field according to Scopus, showcasing its growing influence despite the competitive environment. The absence of Open Access reflects a traditional scholarly publishing model, allowing for meticulous peer-review processes to ensure the rigor and reliability of published studies. This journal aims to foster innovative research, critical reviews, and clinical studies, thereby contributing to a deeper understanding of rheumatic diseases and enhancing patient care. The dedicated readership, including researchers, healthcare professionals, and students, will find valuable insights into the latest findings and methodologies relevant to rheumatology in the journal's comprehensive articles.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.